In HPRCC, MET inhibitors gaveencouraging results in in vitrostudies, but clinical trials have started very recently and although data onthe antitumor activity of the anti-MET compounds are not yet available, thesestudies have shown that MET inhibition results in low-grade toxicity, inagreement with the preclinical analyses performed in animal models [61, 62]. The gene discussed is MET; the disease is papillary renal cell carcinoma.